VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HUM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HUMHumana Inc.
$461.12$55.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksHUMCash Flow

Humana Inc. (HUM) Cash Flow Statement

30Y historyFree accessUpdated daily

Operating cash flow turned negative in 2026Q2 and 2025Q4, with OCF-to-net-income ratios ranging from -0.61 to 13.35, and cumulative net portfolio purchases of roughly $22.5B against $19.0B in sales indicate float is being deployed rather than drawn upon.

Income StatementBalance SheetCash FlowRatios

HUM Cash Flow Statement

Annual statement

HUM Cash Flow Statement

Humana Inc. (HUM) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations1.34B921M2.97B3.98B4.59B2.26B5.64B5.28B2.17B4.05B1.94B868M1.62B1.72B1.92B2.08B2.24B1.42B982.31M1.22B1.69B625.63M347.81M413.14M321.41M148.96M40M217M76M289M341M
Operating CF Growth %55.22%-68.95%-25.5%-13.21%102.79%-59.89%6.72%143.17%-46.36%109.25%123.04%-46.35%-5.71%-10.76%-7.5%-7.26%57.7%44.72%-19.76%-27.42%169.6%79.88%-15.81%28.54%115.77%272.39%-81.57%185.53%-73.7%-15.25%127.33%
Operating CF / Revenue %0.87%0.71%2.52%3.74%4.94%2.7%7.31%8.14%3.82%7.53%3.56%1.6%3.34%4.15%4.91%5.64%6.62%4.59%3.38%4.84%7.88%4.34%2.65%3.38%2.85%1.46%0.38%2.13%0.77%3.6%5.02%
Net Income1.25B1.2B1.21B2.49B2.8B2.93B3.37B2.71B1.68B2.45B614M1.28B1.15B1.23B1.22B1.42B1.1B1.04B647.15M833.68M487.42M308.48M280.01M228.93M142.75M117.17M90M-394M129M173M12M
Depreciation & Amortization763M824M968M917M845M713M616M575M534M485M465M447M449M426M338M303M262.91M250.27M220.35M184.81M148.6M128.86M117.79M126.78M120.73M171.02M147M124M128M108M98M
Stock-Based Compensation231M241M207M175M216M180M181M163M137M157M115M109M98M92M82M67M62.95M65.87M55.37M42.13M32.56M11.32M4.02M6.34M00-30M0000
Deferred Taxes075M-192M-167M-100M15M195M162M194M132M-71M-2M-64M42M-80M22M-198.98M-26.79M-22M-32.74M70.06M-38.36M53.61M32.25M49.56M56.1M19M5M26M40M-25M
Other Non-Cash Items1.19B375M615M486M290M-1.02B-863M14M792M141M66M-346M22M71M46M50M57.53M-19.48M97.52M37.91M-1.41B-400M27.93M-48.56M-124.33M146.45M26M472M17M6M72M
Working Capital Changes-2.08B-1.8B154M81M534M-556M2.14B1.66B-1.17B688M747M-616M-34M-146M315M218M957.99M112.04M-16.08M158.46M2.35B615.33M-135.55M67.4M113.62M-337.43M-212M21M-224M-38M184M
Cash from Investing-4.26B2.27B-2.95B-3.49B-1.01B-6.56B-3.06B-1.28B-3.09B-2.94B-1.36B320M-63M-1.18B-1.97B-1.36B-1.81B-1.86B-498.32M-1.85B-1.65B-767.28M-624.08M-373.16M-128.16M-118.81M-178M18M7M-664M-174M
Capital Expenditures-592M-546M-575M-1B-1.14B-1.34B-964M-736M-612M-526M-527M-523M-528M-437M-410M-336M-222.3M-185.45M-261.57M-239.24M-193.15M-165.85M-114.1M-101.27M-112.14M-114.97M-135M-89M-104M-73M-72M
Acquisitions-1.08B-81M-89M-233M2.36B-4.19B-709M542M-2.25B-31M-7M1.02B54M-153M-1.24B-226M-832.45M-12.44M-422.92M-493.49M-28.06M-402.84M-141.81M00-27.89M16M-14M12M-669M-6M
Purchase of Investments-8.31B-6.44B-8.19B-7.55B-6.05B-7.2B-9.13B-6.36B-4.69B-6.26B-6.57B-6.74B-2.88B-3.26B-3.22B-3.68B-4.59B-7.2B-5.68B-3.49B-4.27B-3.72B-4.11B-4.57B-2.57B-1.87B-1.21B-781M-1.04B-608M-440M
Sale/Maturity of Investments5.92B9.42B6.36B5.09B3.8B6.14B7.73B5.82B4.47B3.88B5.74B6.56B3.29B2.67B2.9B2.88B3.83B5.22B5B3.06B3.41B3.48B3.7B4.29B2.55B1.9B1.13B863M1.17B648M356M
Other Investing-195M-82M-461M210M17M26M0-542M-2.12B2M-828M1M483M-554M-1.55B64M66K313.78M871.69M-682.54M-570.76M34.73M39.14M11.18M1.85M15.32M21M39M-38M38M-12M
Cash from Financing2.08B-1.22B-2.49B-856M-1.91B3.02B-1.96B-2.29B-785M-945M732M-552M-758M-702M-29M-1.02B-371.26M80.84M-554.02M921.28M975.64M293.59M-75.05M170.07M-123.31M-36.29M-182M-170M51M680M-27M
Dividends Paid-429M-430M-431M-431M-392M-354M-323M-291M-265M-220M-177M-172M-172M-168M-165M-82M000000000000000
Share Repurchases-152M-151M-817M-1.57B-2.1B-79M-1.82B-1.07B-1.09B-3.37B-104M-385M-872M-531M-518M-541M-108.55M-22.84M-106.07M-27.41M-26.21M-2.36M-96.59M-44.15M-74.03M-1.87M-26.43M0000
Stock Issued000000000000000000061.64M48.73M38.23M27.62M27.68M0000000
Debt Issuance (Net)-1000K1000K1000K1000K-1000K1000K1000K-1000K1000K1000K01000K1000K01000K-1000K-1000K-1000K1000K1000K1000K1000K-1000K1000K-1000K-1000K-1000K-1000K1000K1000K-1000K
Other Financing2.49B-1.06B-1.46B725M1.97B-310M-890M-511M-595M1.89B1.01B-260M-878M-3M-375M-291M-227.26M203.76M-595.81M623.07M109.14M0-8.65M28.23M6.6M-6.64M-2.69M-13.99M35M14M1M
Net Change in Cash-846M1.98B-2.47B-367M1.67B-1.28B619M1.71B-1.7B165M1.31B636M797M-168M-71M-296M59.55M-356.83M-70.03M300.15M1.01B151.94M-351.32M210.05M69.94M-6.14M-320M65M134M305M140M
Exchange Rate Effect0000000000000000000000000000000
Cash at Beginning6.89B2.22B4.69B5.06B3.39B4.67B4.05B2.34B4.04B3.88B2.57B1.94B1.14B1.31B1.38B1.67B1.61B1.97B2.04B1.74B732.02M580.08M931.4M721.36M651.42M657.56M978M913M779M322M182M
Cash at End6.93B4.2B2.22B4.69B5.06B3.39B4.67B4.05B2.34B4.04B3.88B2.57B1.94B1.14B1.31B1.38B1.67B1.61B1.97B2.04B1.74B732.02M580.08M931.4M721.36M651.42M658M978M913M627M322M
Free Cash Flow747M375M2.39B2.98B3.45B920M4.67B4.55B1.56B3.52B1.41B345M1.09B1.28B1.51B1.74B2.02B1.24B720.74M985.02M1.49B459.78M233.71M311.87M209.27M33.99M-95M128M-28M216M269M
FCF Growth %-51.71%-84.32%-19.68%-13.71%275%-80.32%2.79%191.35%-55.72%150.18%308.41%-68.35%-14.78%-15.47%-13.2%-13.69%63.37%71.51%-26.83%-34.05%224.84%96.73%-25.06%49.03%515.74%135.78%-174.22%557.14%-112.96%-19.7%180.21%
FCF Margin %0.48%0.29%2.03%2.8%3.71%1.1%6.06%7%2.74%6.55%2.59%0.64%2.25%3.1%3.87%4.73%5.96%3.99%2.48%3.89%6.97%3.19%1.78%2.55%1.86%0.33%-0.9%1.25%-0.28%2.69%3.96%
FCF per Share6.133.119.7823.9227.157.1135.1533.7611.2824.219.342.286.998.049.2610.3911.897.314.275.88.892.791.441.921.220.2-0.570.76-0.171.31.63

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile operating cash conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Claims Outflows Drive Cash Volatility

Based on Humana's reported figures, quarterly claims and loss outflows rose from $25.0B in 2024Q2 to $36.3B in 2026Q3, a 45% increase that now dominates the company's cash profile and leaves little margin for timing mismatches between premium receipts and medical payments.

The steady climb in claims outflows tracks the membership and premium expansion visible in revenue, but the pace of growth in claims appears to have kept close to premium growth rather than pulling ahead of it. Because operating cash flow swung sharply between quarters, from $2.2B in 2026Q3 to negative $426M in 2026Q2, the timing of claim payments relative to premium collection appears to be the dominant short-term driver. Investors should monitor whether the seasonal year-end pattern, in which losses cluster in fourth quarters, continues to produce cash strain.

Float Generation Turns Erratic Quarterly

As reported in financial statements, operating cash flow ran positive in six of the ten quarters shown but turned negative in 2026Q2 and 2025Q4, with the OCF-to-net-income ratio ranging from negative 0.61 to 13.35, indicating that reported earnings are a poor guide to underlying cash generation.

The wide dispersion in OCF-to-net-income ratios suggests that the float generated by premiums held before claim payment is being absorbed unevenly across the year, rather than accumulating in a steady fashion. A quarter with 13x cash conversion against net income is better read as a timing effect on working balances than as evidence of durable earnings quality. Given the thin net margin of 0.9%, the company's underwriting cash generation appears to depend heavily on reserve and payable timing, which warrants further investigation through the reserve roll-forward.

Net Portfolio Buying Absorbs Operating Inflows

Based on Humana's reported figures, cumulative purchases of investments over the ten quarters total roughly $22.5B against sales of about $19.0B, meaning the company has been a net investor in its portfolio, deploying float into securities rather than drawing on it.

A net purchase pattern is consistent with a company that is growing its invested float as premiums expand, which is a reasonable use of cash in an insurance model. However, the quarters of heaviest buying, such as 2026Q3 and 2025Q3, coincide with periods of weaker operating cash, suggesting that portfolio deployment may be competing with liquidity needs. Investors should monitor whether this net buying persists if operating cash flow remains volatile.

Dividend Commitment Steady Against Thin Cushion

According to reported cash flow data, dividends paid held near $106M to $109M per quarter throughout the period, while buybacks were minimal and irregular, so the dividend remained a fixed outflow that was covered in most quarters but not in every one.

The stability of the dividend outflow indicates management is treating it as a committed distribution rather than a flexible lever. Coverage from operating cash flow was absent in 2026Q2 and 2025Q4, when cash generation turned negative, meaning the payout was funded from balance sheet resources in those periods. Given the modest 7.0% return on equity, the sustainability of the dividend depends on operating cash recovering consistently rather than in isolated quarters.

Earnings Quality Lags Reported Profit Signals

As reported in financial statements, net income was positive in most quarters yet turned negative in 2024Q4 and 2025Q4 at minus $693M and minus $796M, and these loss periods were not uniformly matched by negative operating cash, underscoring that accruals and reserve movements separate reported earnings from cash.

The divergence between net income and operating cash in several quarters suggests that non-cash items, including reserve changes and receivable timing, are materially shaping the reported figures. The fourth-quarter losses coinciding with year-end claims pressure may partly reflect estimation of incurred but unreported claims rather than cash shortfalls. Analysts should treat the latest beat as contingent on whether cash conversion normalizes in subsequent quarters.

What the Cash Statement Obscures

Based on Humana's reported figures, the cash flow statement does not separately isolate reserve development, risk-adjustment clawbacks, or reinsurance recoverables, so cash generation may look healthier or weaker than underlying claims obligations warrant.

Because the supplied cash data aggregates claims outflows without distinguishing prior-period reserve releases from current-year payments, a quarter of strong operating cash could partly reflect slower settlement of incurred but unreported claims rather than durable underwriting improvement. Investors should monitor prior-period development and reserve roll-forward disclosures, as these may reveal whether the reported cash conversion is sustainable. The absence of explicit disclosure on these items in the provided data means their magnitude cannot be verified here and should be treated as an open question.

HUM — Frequently Asked Questions

Quick answers to the most common questions about buying HUM stock.

How much cash does Humana Inc. (HUM) generate from operations?

Humana Inc. (HUM) generated $921.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Humana Inc.'s free cash flow?

Humana Inc. (HUM) generated $375.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Humana Inc.'s capital expenditure (CapEx)?

Humana Inc. (HUM) spent $546.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Humana Inc. distribute cash to shareholders?

In 2025, Humana Inc. (HUM) returned $430.0M to shareholders via cash dividends and spent $151.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.